300878.SZ Stock Analysis
30
Uncovered
Zhejiang Wecome Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Zhejiang Wecome Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of modern Chinese and western medicines. The company is headquartered in Lishui, Zhejiang and currently employs 1,100 full-time employees. The company went IPO on 2020-08-24. The firm's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The firm mainly conducts its businesses in the China market.